Compare eBay Inc (EBAY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
eBay Inc vs Recursion Pharmaceuticals Inc — how do they compare? eBay Inc trades at $111.88 (market cap $49.83B), while Recursion Pharmaceuticals Inc trades at $4.33 (market cap $2.14B). The key difference: eBay Inc is far larger — about 23.3× Recursion Pharmaceuticals Inc's market cap, and eBay Inc pays a 1.11% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold eBay Inc for 134 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| EBAY | RXRX | |
|---|---|---|
Market Cap | $49.83B | $2.14B |
Volume | 2,986,953 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $118.96 | $6.79 |
52-Week Low | $79.41 | $2.84 |
Typical Hold Time | 134 Days | 23 Days |
Enterprise Value | $53.65B | $1.66B |
Dividend Yield | 1.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EBAY trades at $112.19, up 4.27% today, showing strong momentum with consistent earnings beats in recent quarters. The stock maintains bullish technical signals with moving averages supporting upward trends, while fundamentals reveal robust profitability with 72.05% gross margins and 18.57% net income margins. Recent corporate developments include a $0.31 dividend declaration and strategic focus on collectibles and live commerce growth initiatives.
EBAY presents a favorable risk-reward profile with analyst consensus target of $117.68 offering 4.9% upside potential. The company's strong cash flow generation and debt reduction strategy provide financial stability, though competitive pressures from Amazon's multi-platform tools and slowing advertising growth present headwinds. Institutional sentiment remains positive with 49% buy ratings.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
